FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3080098141> ?p ?o ?g. }

• W3080098141 endingPage "2704" @default.
• W3080098141 startingPage "2688" @default.
• W3080098141 abstract "Treatment of patients with ANCA-associated vasculitis (AAV) and severe renal involvement is not established. We describe outcomes in response to rituximab (RTX) versus cyclophosphamide (CYC) and plasma exchange (PLEX).A retrospective cohort study of MPO- or PR3-ANCA-positive patients with AAV (MPA and GPA) and severe kidney disease (eGFR <30 ml/min per 1.73 m2). Remission, relapse, ESKD and death after remission-induction with CYC or RTX, with or without the use of PLEX, were compared.Of 467 patients with active renal involvement, 251 had severe kidney disease. Patients received CYC (n=161) or RTX (n=64) for remission-induction, and 51 were also treated with PLEX. Predictors for ESKD and/or death at 18 months were eGFR <15 ml/min per 1.73 m2 at diagnosis (IRR 3.09 [95% CI 1.49 to 6.40], P=0.002), renal recovery (IRR 0.27 [95% CI 0.12 to 0.64], P=0.003) and renal remission at 6 months (IRR 0.40 [95% CI 0.18 to 0.90], P=0.027). RTX was comparable to CYC in remission-induction (BVAS/WG=0) at 6 months (IRR 1.37 [95% CI 0.91 to 2.08], P=0.132). Addition of PLEX showed no benefit on remission-induction at 6 months (IRR 0.73 [95% CI 0.44 to 1.22], P=0.230), the rate of ESKD and/or death at 18 months (IRR 1.05 [95% CI 0.51 to 2.18], P=0.891), progression to ESKD (IRR 1.06 [95% CI 0.50 to 2.25], P=0.887), and survival at 24 months (IRR 0.54 [95% CI 0.16 to 1.85], P=0.330).The apparent benefits and risks of using CYC or RTX for the treatment of patients with AAV and severe kidney disease are balanced. The addition of PLEX to standard remission-induction therapy showed no benefit in our cohort. A randomized controlled trial is the only satisfactory means to evaluate efficacy of remission-induction treatments in AAV with severe renal involvement." @default.
• W3080098141 created "2020-09-01" @default.
• W3080098141 creator A5002392240 @default.
• W3080098141 creator A5012967877 @default.
• W3080098141 creator A5016305379 @default.
• W3080098141 creator A5022570560 @default.
• W3080098141 creator A5022727703 @default.
• W3080098141 creator A5036693078 @default.
• W3080098141 creator A5042344779 @default.
• W3080098141 creator A5050933299 @default.
• W3080098141 creator A5054059203 @default.
• W3080098141 creator A5057558630 @default.
• W3080098141 creator A5069733605 @default.
• W3080098141 creator A5070083680 @default.
• W3080098141 creator A5070946918 @default.
• W3080098141 creator A5073207965 @default.
• W3080098141 creator A5078054821 @default.
• W3080098141 creator A5081992519 @default.
• W3080098141 creator A5088965744 @default.
• W3080098141 date "2020-08-21" @default.
• W3080098141 modified "2023-10-17" @default.
• W3080098141 title "Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis with Severe Kidney Disease" @default.
• W3080098141 cites W1511911200 @default.
• W3080098141 cites W1583701208 @default.
• W3080098141 cites W1685331907 @default.
• W3080098141 cites W1964824588 @default.
• W3080098141 cites W1967599448 @default.
• W3080098141 cites W1969399531 @default.
• W3080098141 cites W1973885323 @default.
• W3080098141 cites W1997786943 @default.
• W3080098141 cites W1999520120 @default.
• W3080098141 cites W2000625141 @default.
• W3080098141 cites W2000728146 @default.
• W3080098141 cites W2009150197 @default.
• W3080098141 cites W2011309580 @default.
• W3080098141 cites W2015836326 @default.
• W3080098141 cites W2025060860 @default.
• W3080098141 cites W2031517139 @default.
• W3080098141 cites W2033723052 @default.
• W3080098141 cites W2043793244 @default.
• W3080098141 cites W2049483863 @default.
• W3080098141 cites W2063340779 @default.
• W3080098141 cites W2070018038 @default.
• W3080098141 cites W2084056567 @default.
• W3080098141 cites W2100468967 @default.
• W3080098141 cites W2107439016 @default.
• W3080098141 cites W2108422147 @default.
• W3080098141 cites W2109207289 @default.
• W3080098141 cites W2113281485 @default.
• W3080098141 cites W2120427700 @default.
• W3080098141 cites W2121690051 @default.
• W3080098141 cites W2122611620 @default.
• W3080098141 cites W2137794033 @default.
• W3080098141 cites W2151319492 @default.
• W3080098141 cites W2155965977 @default.
• W3080098141 cites W216005197 @default.
• W3080098141 cites W2163003110 @default.
• W3080098141 cites W2163274590 @default.
• W3080098141 cites W2171643265 @default.
• W3080098141 cites W2171950933 @default.
• W3080098141 cites W2264075806 @default.
• W3080098141 cites W2418168454 @default.
• W3080098141 cites W2464200809 @default.
• W3080098141 cites W2620110075 @default.
• W3080098141 cites W2746848409 @default.
• W3080098141 cites W2779456451 @default.
• W3080098141 cites W2789699981 @default.
• W3080098141 cites W3004897282 @default.
• W3080098141 cites W4317639305 @default.
• W3080098141 cites W4317707712 @default.
• W3080098141 doi "https://doi.org/10.1681/asn.2019111197" @default.
• W3080098141 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7608964" @default.
• W3080098141 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32826324" @default.
• W3080098141 hasPublicationYear "2020" @default.
• W3080098141 type Work @default.
• W3080098141 sameAs 3080098141 @default.
• W3080098141 citedByCount "45" @default.
• W3080098141 countsByYear W30800981412020 @default.
• W3080098141 countsByYear W30800981412021 @default.
• W3080098141 countsByYear W30800981412022 @default.
• W3080098141 countsByYear W30800981412023 @default.
• W3080098141 crossrefType "journal-article" @default.
• W3080098141 hasAuthorship W3080098141A5002392240 @default.
• W3080098141 hasAuthorship W3080098141A5012967877 @default.
• W3080098141 hasAuthorship W3080098141A5016305379 @default.
• W3080098141 hasAuthorship W3080098141A5022570560 @default.
• W3080098141 hasAuthorship W3080098141A5022727703 @default.
• W3080098141 hasAuthorship W3080098141A5036693078 @default.
• W3080098141 hasAuthorship W3080098141A5042344779 @default.
• W3080098141 hasAuthorship W3080098141A5050933299 @default.
• W3080098141 hasAuthorship W3080098141A5054059203 @default.
• W3080098141 hasAuthorship W3080098141A5057558630 @default.
• W3080098141 hasAuthorship W3080098141A5069733605 @default.
• W3080098141 hasAuthorship W3080098141A5070083680 @default.
• W3080098141 hasAuthorship W3080098141A5070946918 @default.
• W3080098141 hasAuthorship W3080098141A5073207965 @default.
• W3080098141 hasAuthorship W3080098141A5078054821 @default.
• W3080098141 hasAuthorship W3080098141A5081992519 @default.

• next